AcuCort has published its newsletter for March 2026. The newsletter features a CEO statement by Jonas Jönmark as well as two articles: one on the company now operating its pharmacovigilance system in-house, and one on Zeqmelits® being suitable for more indications than acute allergic reaction, where AcuCort sees opportunities primarily within two areas.

The newsletter is available here: https://bit.ly/acucort-spring-2026 

For further information: 
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.